NEW YORK (GenomeWeb) – Molecular diagnostics company MolecularMD announced today that it has received CE marking for a custom companion diagnostic it developed for a Daiichi Sankyo clinical trial.

The Phase II trial is testing a cancer therapy in Europe, MolecularMD said. The firm's assay is being used to select patients to participate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.